0000899243-22-036575.txt : 20221121
0000899243-22-036575.hdr.sgml : 20221121
20221121190442
ACCESSION NUMBER: 0000899243-22-036575
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221117
FILED AS OF DATE: 20221121
DATE AS OF CHANGE: 20221121
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HIGGINS JOHN L
CENTRAL INDEX KEY: 0001208906
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33093
FILM NUMBER: 221407095
MAIL ADDRESS:
STREET 1: 11119 NORTH TORREY PINES ROAD, SUITE 200
CITY: LA JOLLA
STATE: CA
ZIP: 92037
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: LIGAND PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000886163
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 770160744
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3911 SORRENTO VALLEY BLVD
STREET 2: SUITE 110
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-550-7500
MAIL ADDRESS:
STREET 1: 3911 SORRENTO VALLEY BLVD
STREET 2: SUITE 110
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-11-17
0
0000886163
LIGAND PHARMACEUTICALS INC
LGND
0001208906
HIGGINS JOHN L
3911 SORRENTO VALLEY BOULEVARD,
SUITE 110
SAN DIEGO
CA
92121
1
1
0
0
Chief Executive Officer
Common Stock
2022-11-17
4
S
0
10000
78.3173
D
416731
D
Common Stock
2022-11-18
4
M
0
10000
12.78
A
426731
D
Non-Qualified Stock Option (right to buy)
12.78
2022-11-18
4
M
0
10000
0.00
D
2023-02-15
Common Stock
10000
40335
D
The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on September 22, 2022, in accordance with Rule 10b5-1.
Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The original date of grant was 02/15/13.
/s/ Andrew Reardon, Attorney-in-Fact for John L. Higgins
2022-11-21